CorMedix, Inc., a developmental-stage biopharmaceutical company, announced the appointment of a new Chief Medical Officer (CMO), Mark A. Klausner, M.D. Dr. Klausner has over 25 years of pharmaceutical experience in various functional and therapeutic areas, which includes comprehensive experience in the areas of nephrology and cardiovascular therapeutic areas.
Dr. Klausner joins the CorMedix team from Nephrogenex, Inc., a developmental biotechnology corporation, where he acted as Chief Medical Officer since 2007. Dr. Klausner held the responsibility to strategize and execute Nephrogenex’s clinical trials and regulatory compliance, which includes its submissions and correspondence with the Food and Drug Administration (FDA). Preceding Nephrogenex, Dr.Klausner held many vice presidential roles at Johnson & Johnson (J&J) since 1990, in areas of medical affairs, domestic and global drug safety and surveillance, and clinical R&D.
Before J&J, Dr. Klausner held director positions at Wyeth Pharmaceuticals in cardiovascular clinical research and OTC clinical research. Dr. Klausner also was a member of a private practice, multi-specialty internal medicine group where he was one of the two nephrologists with responsibilities for an outpatient dialysis center, in-hospital dialysis and nephrology consultations, and office based practice prior to his pharmaceutical experiences.
Dr.Klausner has also been involved in various New Drug Applications and supplemental New Drug Applications. While working at J&J, he was the head company presenter at two public FDA Advisory Committee meetings, which resulted in new drug approvals. Dr. Klausner holds board certification in both nephrology and internal medicine. He has received his medical degree from the prestigious Harvard Medical School. His internship was completed in Internal Medicine at Columbia Presbyterian Hospital, located in New York City, later returning to Harvard to complete his Internal Medicine residency and nephrology fellowship at Beth Israel Hospital in Boston. He has extensive interaction with the nephrology community and regulatory bodies, and has written a plethora of publications in peer-reviewed medical journals.
Dr. Klausner stated, “I am excited to join CorMedix at this particular stage of the company’s growth cycle. With an ongoing phase II study of deferiprone (CRMD001) and the expected initiation of a pivotal study of Neutrolin® (CRMD003) this year, it is an opportune time for me to join the team. I look forward to contributing significantly to the further clinical advancement of the company’s product candidates.”
John C. Houghton, President and Chief Executive Officer of CorMedix, commented, “We are delighted to have Mark join us as CMO. He brings a successful track record as an executive in diverse areas of pharmaceutical medicine, including significant strategic and tactical clinical trial management experience and regulatory approvals. Dr. Klausner’s extensive clinical trials experience will be of great value in shepherding our phase II clinical trial program for deferiprone and our expected pivotal late stage clinical trial program for Neutrolin forward with the FDA and other global regulatory authorities.”
Dr. Klausner is a successor of Dr. Mark Houser as CorMedix’s CMO. Dr. Houser’s term ended on February 28, 2011 in accordance with his agreement for employment.
For more information on CorMedix Inc. and its products and treatments, visit their website: www.cormedix.com